LENZ THERAPEUTICS, INC. Proceeds from Issuance of Convertible Preferred Stock
LENZ THERAPEUTICS, INC. (LENZ) reported Proceeds from Issuance of Convertible Preferred Stock of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2025-03-19
- LENZ THERAPEUTICS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2024-12-31 was $0.00.
- LENZ THERAPEUTICS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2024-09-30 was $0.00.
- LENZ THERAPEUTICS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2024-06-30 was $0.00.
- LENZ THERAPEUTICS, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. proceeds from issuance of convertible preferred stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- LENZ THERAPEUTICS, INC. proceeds from issuance of convertible preferred stock for fiscal 2023 was $82.98M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $0.00 derived: sum of 2 quarters · filed 2025-03-19 | $0.00 derived: sum of 3 quarters · filed 2025-03-19 | $0.00 10-K · filed 2025-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-03-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-03-19 | $0.00 derived: sum of 4 quarters · filed 2025-03-19 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-03-19 | $0.00 derived: sum of 3 quarters · filed 2025-03-19 | $0.00 derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $0.00 derived: sum of 2 quarters · filed 2025-03-19 | $0.00 derived: sum of 3 quarters · filed 2025-03-19 | $82.98M 10-K · filed 2025-03-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $82.98M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $82.98M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $82.98M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |